The Conversation (0)
Corbus Pharmaceuticals Holdings announced the start of their phase 2 clinical study of anabasum, treating systemic lupus erythematosus.
Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) announced the start of their phase 2 clinical study of anabasum, treating systemic lupus erythematosus (SLE).
As quoted in the press release:
SLE is an uncommon autoimmune disease associated with significant morbidity, reduction in quality of life and a 2.4-fold increase in standard mortality rate. The disease affects primarily women of child-bearing age, with increased prevalence and morbidity among African Americans and other minority populations.
This Phase 2 SLE clinical trial is being conducted by the Autoimmunity Centers of Excellence (ACE) program, which is funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). Cynthia Aranow, M.D., of the Feinstein Institute for Medical Research (FIMR), Manhasset, NY, is Principal Investigator for ACE, and Meggan Mackay, M.D., M.S., is Principal Investigator for the clinical trial of anabasum in SLE. Drs. Aranow and Mackay are Investigators at the Center for Autoimmunity & Musculoskeletal Disease at FIMR and Associate Professors of Molecular Medicine at Hofstra Northwell School of Medicine.
Click here to read the full press release.
Source: www.marketwired.com
